Use of Iron Sucrose in Infants
Iron sucrose is the preferred intravenous iron formulation for infants with iron-deficiency anemia refractory to oral iron, dosed at 0.5 mg/kg (maximum 100 mg per dose) given as a slow IV injection over 5 minutes or diluted infusion over 5-60 minutes. 1, 2
Dosing and Administration
Standard Dosing Protocol
- Dose: 0.5 mg/kg per infusion, not exceeding 100 mg per dose 2
- Frequency: Every 2-4 weeks depending on clinical context 2
- Route: Either undiluted slow IV injection over 5 minutes OR diluted in 0.9% NaCl at 1-2 mg/mL concentration over 5-60 minutes 2
- Critical: Do not dilute below 1 mg/mL concentration 2
Age-Specific Considerations
While FDA approval is for children ≥2 years, emerging evidence supports use in younger infants with appropriate precautions. Recent data from 2023 demonstrated safety and efficacy in infants as young as 4 months with intestinal failure 3. The 2018 ESPGHAN/ESPEN guidelines note iron sucrose is the most studied IV iron preparation in children with rare severe adverse events 1.
Safety Profile
Adverse Reactions
Iron sucrose has a superior safety profile compared to iron dextran, with no test dose required 1. In pediatric studies totaling 232 children receiving 1,624 doses, very few serious reactions occurred 1:
- Most common: Mild injection site reactions and transient taste changes 4
- Serious reactions: Extremely rare, primarily when exceeding maximum 300 mg dose 1
- Critical warning: One case of hepatocellular toxicity occurred at 16 mg/kg dose—never exceed recommended dosing 1
Monitoring Requirements
- Baseline: Hemoglobin, ferritin before treatment 1
- Follow-up: Check hemoglobin at 4-6 weeks post-infusion (peak response time) 3
- Long-term: Monitor ferritin and hemoglobin regularly to prevent both deficiency and overload 1
Clinical Algorithm for Use
When to Use IV Iron Sucrose
- Oral iron failure: Non-response or intolerance to adequate oral iron trial
- Transfusion avoidance: When blood transfusion must be avoided 4
- Malabsorption: Intestinal failure, inflammatory bowel disease, celiac disease 3, 5
- Chronic conditions: Chronic kidney disease (FDA-approved indication) 2
Contraindications to Oral Iron (Favoring IV Route)
- Severe gastrointestinal side effects limiting compliance
- Malabsorptive conditions preventing adequate absorption
- Need for rapid iron repletion
- Chronic blood loss exceeding oral replacement capacity
Practical Considerations
Infusion Preparation
For a typical infant weighing 10 kg:
- Dose: 5 mg (0.5 mg/kg × 10 kg = 5 mg)
- Volume: 0.25 mL of iron sucrose (20 mg/mL concentration)
- Dilution: Mix in 5 mL of 0.9% NaCl (final concentration 1 mg/mL)
- Infusion time: 5-60 minutes
Expected Response
- Hemoglobin increase: Approximately 1.9 g/dL within 4 weeks 3
- Complete normalization: Typically 31-42 days after first infusion 4
- Iron stores: Replenished more rapidly than with oral therapy
Common Pitfalls to Avoid
- Exceeding maximum dose: Never give >100 mg per dose in infants—risk of serious toxicity 1, 2
- Inadequate dilution: Concentrations <1 mg/mL may cause instability 2
- Premature discontinuation: Continue monitoring even after hemoglobin normalizes to ensure iron stores are replete
- Ignoring underlying cause: Always investigate and address the reason for oral iron failure
- Over-supplementation: Monitor ferritin to prevent iron overload, particularly in patients requiring repeated courses 1
Alternative Formulations
While iron sucrose is preferred based on pediatric safety data 1, other options exist if unavailable:
- Iron gluconate: Limited pediatric data, doses 0.75-1.5 mg/kg 1
- Ferric carboxymaltose: Minimal infant data, requires phosphorus monitoring 6
- Avoid iron dextran: Higher allergic reaction risk, requires test dose 1
Iron sucrose remains the gold standard for IV iron therapy in infants due to extensive safety data, no test dose requirement, and proven efficacy across multiple pediatric studies. 1